Item 7.01. Regulation FD.

On October 20, 2008, we issued a joint press release with our corporate partner, Forest Laboratories, Inc., in which we announced that the U.S. Food and Drug Administration has advised us that it was not able to take final action by the scheduled Prescription Drug User Fee Act action date of October 18, 2008, on the New Drug Application for milnacipran; a selective serotonin and norepinephrine dual reuptake inhibitor, for the management of fibromyalgia. The text of this press release is set forth as Exhibit 99.1.
In accordance with general instructions B.6 of Form 8-K, the information in this report, including Exhibit 99.1, is furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:
The following exhibit relating to Item 7.01 shall be deemed to be furnished, and not filed.
99.1 Press Release dated October 20, 2008.

---

Table of Contents